Info
Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby reducing lymphopenia and inflammatory cell death in patients with viral infections and restoring the anti-tumor immune response in cancer patients.
- Website
-
http://www.apogenix.com
Externer Link zu Apogenix GmbH
- Branche
- Biotechnologieforschung
- Größe
- 51–200 Beschäftigte
- Art
- Privatunternehmen
- Gegründet
- 2005
- Spezialgebiete
- Development of immunotherapeutics, TNF superfamily signaling, Drug candidates for cancer treatment, CD95, Glioblastoma, Myelodysplastic syndromes und COVID-19
Orte
-
Primär
Wegbeschreibung
-
Wegbeschreibung
Heidelberg, DE